Dupilumab Gets Priority Review for Prurigo Nodularis
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dupilumab for the treatment of adults with prurigo nodularis. The target action date for the FDA’s decision…